Literature DB >> 26168083

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation.

Samir Tivari1, Reju Korah1, Michael Lindy1, Robert Wieder2.   

Abstract

The study of breast cancer dormancy in the bone marrow is an exceptionally difficult undertaking due to the complexity of the interactions of dormant cells with their microenvironment, their rarity and the overwhelming excess of hematopoietic cells. Towards this end, we developed an in vitro 2D clonogenic model of dormancy of estrogen-sensitive breast cancer cells in the bone marrow. The model consists of a few key elements necessary for dormancy. These include 1) the use of estrogen sensitive breast cancer cells, which are the type likely to remain dormant for extended periods, 2) incubation of cells at clonogenic density, where the structural interaction of each cell is primarily with the substratum, 3) fibronectin, a key structural element of the marrow and 4) FGF-2, a growth factor abundantly synthesized by bone marrow stromal cells and heavily deposited in the extracellular matrix. Cells incubated with FGF-2 form dormant clones after 6 days, which consist of 12 or less cells that have a distinct flat appearance, are significantly larger and more spread out than growing cells and have large cytoplasm to nucleus ratios. In contrast, cells incubated without FGF-2 form primarily growing colonies consisting of>30 relatively small cells. Perturbations of the system with antibodies, inhibitors, peptides or nucleic acids on day 3 after incubation can significantly affect various phenotypic and molecular aspects of the dormant cells at 6 days and can be used to assess the roles of membrane-localized or intracellular molecules, factors or signaling pathways on the dormant state or survival of dormant cells. While recognizing the in vitro nature of the assay, it can function as a highly useful tool to glean significant information about the molecular mechanisms necessary for establishment and survival of dormant cells. This data can be used to generate hypotheses to be tested in vivo models.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26168083      PMCID: PMC4652423          DOI: 10.3791/52672

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  36 in total

1.  Integrin alpha5beta1 promotes survival of growth-arrested breast cancer cells: an in vitro paradigm for breast cancer dormancy in bone marrow.

Authors:  Reju Korah; Monika Boots; Robert Wieder
Journal:  Cancer Res       Date:  2004-07-01       Impact factor: 12.701

2.  Luminal breast cancer metastasis is dependent on estrogen signaling.

Authors:  Vidya Ganapathy; Whitney Banach-Petrosky; Wen Xie; Aparna Kareddula; Hilde Nienhuis; Gregory Miles; Michael Reiss
Journal:  Clin Exp Metastasis       Date:  2012-03-17       Impact factor: 5.150

3.  Genes and regulatory pathways involved in persistence of dormant micro-tumors.

Authors:  Nava Almog
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

4.  Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients.

Authors:  S Braun; C Kentenich; W Janni; F Hepp; J de Waal; F Willgeroth; H Sommer; K Pantel
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

5.  An in vitro system to study tumor dormancy and the switch to metastatic growth.

Authors:  Dalit Barkan; Jeffrey E Green
Journal:  J Vis Exp       Date:  2011-08-11       Impact factor: 1.355

6.  Differential temporal and spatial gene expression of fibroblast growth factor family members during mouse mammary gland development.

Authors:  S Coleman-Krnacik; J M Rosen
Journal:  Mol Endocrinol       Date:  1994-02

7.  Kinetics of metastatic breast cancer cell trafficking in bone.

Authors:  Pushkar A Phadke; Robyn R Mercer; John F Harms; Yujiang Jia; Andra R Frost; Jennifer L Jewell; Karen M Bussard; Shakira Nelson; Cynthia Moore; John C Kappes; Carol V Gay; Andrea M Mastro; Danny R Welch
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

8.  Expression and localization of members of the fibroblast growth factor family in the bovine mammary gland.

Authors:  A Plath; R Einspanier; C Gabler; F Peters; F Sinowatz; D Gospodarowicz; D Schams
Journal:  J Dairy Sci       Date:  1998-10       Impact factor: 4.034

9.  Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer.

Authors:  Ina H Benoy; Roberto Salgado; Hilde Elst; Peter Van Dam; Joost Weyler; Eric Van Marck; Simon Scharpé; Peter B Vermeulen; Luc Y Dirix
Journal:  Breast Cancer Res       Date:  2005-01-10       Impact factor: 6.466

10.  The perivascular niche regulates breast tumour dormancy.

Authors:  Cyrus M Ghajar; Héctor Peinado; Hidetoshi Mori; Irina R Matei; Kimberley J Evason; Hélène Brazier; Dena Almeida; Antonius Koller; Katherine A Hajjar; Didier Y R Stainier; Emily I Chen; David Lyden; Mina J Bissell
Journal:  Nat Cell Biol       Date:  2013-06-02       Impact factor: 28.824

View more
  8 in total

Review 1.  Targeting dormant micrometastases: rationale, evidence to date and clinical implications.

Authors:  Robert E Hurst; Anja Bastian; Lora Bailey-Downs; Michael A Ihnat
Journal:  Ther Adv Med Oncol       Date:  2016-03       Impact factor: 8.168

2.  Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer.

Authors:  Kevin Shee; Wei Yang; John W Hinds; Riley A Hampsch; Frederick S Varn; Nicole A Traphagen; Kishan Patel; Chao Cheng; Nicole P Jenkins; Arminja N Kettenbach; Eugene Demidenko; Philip Owens; Anthony C Faber; Todd R Golub; Ravid Straussman; Todd W Miller
Journal:  J Exp Med       Date:  2018-02-07       Impact factor: 14.307

3.  Reawakening of dormant estrogen-dependent human breast cancer cells by bone marrow stroma secretory senescence.

Authors:  Samir Tivari; Haiyan Lu; Tanya Dasgupta; Mariana S De Lorenzo; Robert Wieder
Journal:  Cell Commun Signal       Date:  2018-08-17       Impact factor: 5.712

Review 4.  Stromal Co-Cultivation for Modeling Breast Cancer Dormancy in the Bone Marrow.

Authors:  Robert Wieder
Journal:  Cancers (Basel)       Date:  2022-07-09       Impact factor: 6.575

5.  Transcription Factor Prospero Homeobox 1 (PROX1) as a Potential Angiogenic Regulator of Follicular Thyroid Cancer Dissemination.

Authors:  Magdalena Rudzińska; Michał Mikula; Katarzyna D Arczewska; Ewa Gajda; Stanisława Sabalińska; Tomasz Stępień; Jerzy Ostrowski; Barbara Czarnocka
Journal:  Int J Mol Sci       Date:  2019-11-10       Impact factor: 5.923

Review 6.  In vitro Models of Breast Cancer Metastatic Dormancy.

Authors:  Marco Montagner; Erik Sahai
Journal:  Front Cell Dev Biol       Date:  2020-03-03

7.  Dormancy and NKG2D system in brain metastases: Analysis of immunogenicity.

Authors:  Charlotte Flüh; Victor Mafael; Vivian Adamski; Michael Synowitz; Janka Held-Feindt
Journal:  Int J Mol Med       Date:  2019-12-30       Impact factor: 4.101

Review 8.  Tuning Cancer Fate: Tumor Microenvironment's Role in Cancer Stem Cell Quiescence and Reawakening.

Authors:  Antonella Sistigu; Martina Musella; Claudia Galassi; Ilio Vitale; Ruggero De Maria
Journal:  Front Immunol       Date:  2020-10-21       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.